Overview

Price chart · mood · technical indicators

LPCN

Lipocine Incstock Healthcare

Biotechnology

$2.1929.85%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$1.81$12.37

Current: $2.19

Idea: EMA

1Y Return

+107.0%

Sharpe 3Y

0.59

Market Comparison

vs Healthcare Sector & Biotechnology Industry

LPCN

-29.85%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—Forward 5.64

EPS (TTM)$-1.960.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$18.1MMicro cap

Wall Street coverage

$6.00median target· current $7.05 (-14.9%)2 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 5.64
PEG ratio: 0.00
P/B: 0.82
P/S (TTM): 9.02
EV/EBITDA: 153.43

Profitability & growth

ROE (TTM): -54.4%
Operating margin: -3224.0%
Revenue growth YoY: 27.2%
Dividend yield: —
Beta: 0.50

Last earnings

May 7, 2026 · Estimate $-0.49 · Reported $-0.54

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Lipocine Inc

Company profile

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 675 ARAPEEN DRIVE, SALT LAKE CITY, UT
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$18.1M

Shares outstanding$8.2M

52W high$12.37

52W low$1.81

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

LPCN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP

[8-K] Lipocine Inc. Reports Material Event

LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD

Lipocine’s postpartum depression drug data to be presented at ASCP

Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting

Lipocine (NASDAQ: LPCN) to present LPCN 1154 Phase 3 postpartum depression data

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Oral postpartum depression trial to be showcased at 2026 ASCP meeting

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine (NASDAQ: LPCN) plans fireside chat at A.G.P. Annual Healthcare Company Showcase

Lipocine to Present at A.G.P. Virtual Healthcare Showcase May 20

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Ikarian Capital (LPCN) reports 508,556 shares, 6.3% ownership

Squadron Master Fund LP (LPCN) reports 450,000 shares, 6.2% stake

A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6

Lipocine Inc. Announces First Quarter Financial Results Ending March 31, 2026

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | State News | hjnews.com

About Lipocine Inc

Classification

Company profile

LPCN

Market Comparison

LPCN Market Analysis

Overview

LPCN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP

[8-K] Lipocine Inc. Reports Material Event

LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD

Lipocine’s postpartum depression drug data to be presented at ASCP

Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting

Lipocine (NASDAQ: LPCN) to present LPCN 1154 Phase 3 postpartum depression data

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Oral postpartum depression trial to be showcased at 2026 ASCP meeting

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine (NASDAQ: LPCN) plans fireside chat at A.G.P. Annual Healthcare Company Showcase

Lipocine to Present at A.G.P. Virtual Healthcare Showcase May 20

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Ikarian Capital (LPCN) reports 508,556 shares, 6.3% ownership

Squadron Master Fund LP (LPCN) reports 450,000 shares, 6.2% stake

A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6

Lipocine Inc. Announces First Quarter Financial Results Ending March 31, 2026

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | State News | hjnews.com

About Lipocine Inc

Classification

Company profile

LPCN

Market Comparison